Clinical Trial Update: Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety and tolerability study of rAvPAL-PEG for phenylketonuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• rAvPAL-PEG (recombinant phenylalanine ammonia-lyase enzyme PEGylated)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria | Phase 1 | Status: COMPLETED